ArticleOpen forum infectious diseases2025
High Rates of Mortality During Drug-Resistant Tuberculosis Treatment Among Individuals With Diabetes Mellitus and Low Body Mass Index.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of diabetes mellitus on drug-resistant tuberculosis across resistance categories: a systematic review and meta-analysis.Journal of global health · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes is a risk factor for mortality during rifampicin-resistant tuberculosis (RR-TB) treatment, but whether its impact differs by nutritional status is unknown. We estimated the effect of diabetes and its interaction with low body mass index (BMI) (ie, <18.5 kg/m Methods: We used medical record data of adults treated for RR-TB in Indonesia between March 2020 and May 2022. Diabetes was defined as glycated hemoglobin ≥6.5% or prior diabetes diagnosis by healthcare providers. Cox proportional hazards regression was used to estimate the hazard rates of mortality during treatment comparing those with and without diabetes. Multiplicative and additive interactions were evaluated to determine if the effect of diabetes on mortality during treatment was moderated by BMI status. Results: Among 345 individuals (57% male, 1.7% with human immunodeficiency virus, 59% with BMI <18.5 kg/m Conclusions: Having diabetes doubled the risk of mortality during RR-TB treatment. Highest mortality rates were observed among individuals with combined diabetes and low BMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.